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   1 
ABSTRACT 
 
The central question in this paper is whether it is wise to assume that cosmetics are not 
hazardous, especially in the light of the stem cell hype. Some cosmetics contain stem cell 
extracts or claim to influence the stem cells in the skin. This paper examines the issue of these 
“stem cell creams” in three jurisdictions: Belgium, Europe and the United States.  
  The paper approaches the issues raised by the advent of such products in the following 
manner: first, the classification problem is discussed. Stem cell creams sometimes fall in a 
grey area between cosmetics and drugs. When the categorization is only based on claims 
made of the products, manufacturers can easily evade their responsibilities by manipulating 
the claims.  
The applicable regulations are then analyzed. Although the requirements for drugs are 
similar in the three jurisdictions, this is not the case with respect to cosmetics. Cosmetics are 
clearly regulated more strictly in Europe. Finally, a clear overview of the loopholes in the 
current  regulations  is  offered  and  some  recommendations  for  change  are  proposed.  The 
conclusion  of  the  paper  is  that  the  discussed  stem  cell  creams  might  be  hazardous  and 
therefore, should be rigorously regulated. Moreover, something as superficial as claims by 
manufacturer should not be determinative so as to alter the classification of a product. The 
European model could thus arguably be an inspiration for FDA to base future reforms upon. 
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STEM CELLS INTENDED FOR COSMETIC USE ONLY: 
REGULATION IN BELGIUM, EUROPE AND THE UNITED STATES 
 
Introduction 
 
Today when purchasing a cosmetic one expects that the product will cause no harm. In 
the past, nevertheless, some cosmetics such as lead-based pigments were quite hazardous to 
people’s health.
1 The danger led to the regulation of cosmetics. Because of this regulation, 
people are convinced that the safety of their cosmetics is assured. However, in light of new 
scientific  breakthroughs,  cosmetics  are  not  what  they  used  to  be  anymore.  The  central 
question of this paper is whether it is wise to assume that cosmetics are not hazardous.  The 
paper examines this issue in three jurisdictions: Belgium, Europe and the United States. 
Nowadays many cosmetic companies use extracts of stem cells in their products and 
refer even to them in their labels and advertisements. At the end of 2010, the California-based 
International Stem Cell Corporation started selling anti-aging products in the U.S. developed 
by  its  subsidiary  Lifeline  Skin  Care.  These  moisturizers  contain  patented,  non-embryonic 
(parthenogenetic
2) human stem cell extracts.
3 Another skin care product is called Stemixx and 
is  manufactured  by  Californian  AmStemInc.
4  This  anti-wrinkle  cream  is  a  reformulated 
version of a Stem Cell Facial Cream, which has been sold in Korea under the label “97.7” for 
over two years. The main ingredient is listed as “HSCM,” an abbreviation for Human Stem 
                                                 
1 Charles I. Betton, Risk Assessment and Cosmetics, in 1 GLOBAL REGULATORY ISSUES FOR THE COSMETICS 
INDUSTRY 1, 10 (Charles I. Betton ed., 2007).  
2 Parthenogenesis creates pluripotent human stem cells from unfertilized oocytes. This is not explained on the 
website of the company.  However e.g. Press Release, ISCC Announces Successful Manufacture of New Anti - 
Aging Stem Cell - Based Product Line, SPECIALCHEM, Oct 27, 2010, 
http://www.specialchem4cosmetics.com/services/news.aspx?id=5750 
3 http://www.lifelineskincare.com/ 
4 http://www.amsteminc.com/amstem-products/stemixx-facial-cream/ 
   3 
Cell Conditioned Media Extract, which is composed of nutrients and proteins secreted during 
the culture of stem cells derived from human umbilical cord blood.   
Other  creams  do  not  contain  human  stem  cell  extracts  but  nevertheless  claim  to 
influence the skin’s stem cells. Examples are Lancôme’s Absolue Precious Cells,
5 Amatokin 
Emulsion by Voss Laboratories,
6 ReVive’s Peau Magnifique,
7 Dior’s Capture R60/80 XP,
8 
Emerge Swiss Apple Stem cell serum,
9 StemCellin Intensive Emulsion and StemCellin Deep 
Wrinkle Serum
10.  
Stem  cells  are  clearly  hyped  and  businesses  are  keen  to  take  advantage  of  the 
perceived value of stem cells to positively affect their bottom line.  In this paper I will discuss 
first how creams that are said to influence the user’s own stem cells are classified in Europe 
and in the U.S. Then I will focus on the classification of creams containing stem cells or stem 
cell extracts. After that, I will continue by describing the regulation of both types of stem cell 
creams in Europe and in the U.S. Finally, I will give an overview of the major difficulties in 
the current regulation and conclude with some recommendations. 
 
 
 
 
 
 
 
 
                                                 
5 http://www.lancome-usa.com/Absolue-Precious-Cells/1000362,default,pd.html 
6 http://amatokinstore.com/index.php 
7 http://www.reviveskincare.com/store/shop/Serums_Peau-Magnifique-Youth-Recruit_prod120041 
8 http://www.dior.com/beauty/usa/en/skin_care_by_christian_dior_face_care_body_care_su/face-
skincare/wrinkle_correction/ridesdaynight/ultimate-wrinkle-restoring-serum/py0535530.html 
9 http://www.stemcellskincare.com/Stem_Cell_Skin_Care_Serum.htm 
10 http://www.stemcellfacecream.com   4 
I. Classification of Stem Cell Creams 
 
Despite their name, so-called “stem cell creams” often do not contain human stem 
cells. They do, however, claim to influence the stem cells present in the skin of the consumer 
who applies the cream.  I will discuss first this type of cream. After that I will focus on the 
classification of creams that actually contain human stem cells or stem cell extracts. 
 
A. Creams that Will Influence the Stem Cells in the Skin 
 
    (1) The Belgian/European Classification 
A facial cream, like the one I will discuss in this section namely one that influences 
the stem cells in the skin, seems at first sight the typical example of a cosmetic. The Belgian 
rules on cosmetics (cosmetic products) and drugs (medicinal products) are very similar to the 
European  rules.  This  is  logical  as  Belgium  is  a  member  of  the  European  Union  and  is 
therefore  both  required  to  implement  European  Directives  and  immediately  bound  by 
European Regulations.
11 An anti-aging cream that influences stem cells in the skin could be 
qualified  as  a  cosmetic.  According  to  the  Belgian  Royal  Decree  of  15  October  1997  on 
Cosmetic Products
12 a “cosmetic product” is “any substance or mixture intended to be placed 
in contact with the external parts of the human body (epidermis, hair system, hair, nails, lips 
and external genital organs) or with the teeth and the mucous membranes of the oral cavity 
                                                 
11 A European Directive sets out some goals that Member States need implement by adapting their laws. For 
more information see http://ec.europa.eu/eu_law/introduction/what_directive_en.htm. A European Regulation 
has a more direct power and will have binding force in all Member States from the moment they are passed. For 
more information see http://ec.europa.eu/eu_law/introduction/what_regulation_en.htm. 
12 Art. 1, 1°, Koninklijk Besluit betreffende cosmetica [Royal Decree on Cosmetic Products] of Oct. 15, 1997, 
BELGISCH STAATSBLAD [B.S.] [Official Gazette of Belgium], Jan. 16, 1998, http://www.staatsblad.be: “alle 
stoffen of mengsels die bestemd zijn om in aanraking te worden gebracht met de verschillende delen van het 
menselijk lichaamsoppervlak (de opperhuid, de beharing, het haar, de nagels, de lippen en de uitwendige 
geslachtsorganen) of met de tanden en de mondslijmvliezen, uitsluitend of hoofdzakelijk om deze te reinigen, te 
parfumeren, het uiterlijk ervan te wijzigen en/of de lichaamsgeuren te corrigeren en/of ze te beschermen of ze in 
goede staat te houden”.   5 
with  a  view  exclusively  or  mainly  to  cleaning  them,  perfuming  them,  changing  their 
appearance and/or correcting body odors and/or protecting them or keeping them in good 
condition”.  This definition contains three elements: (1) substance or mixture, (2) the place 
ON  the  body  where  the  product  will  be  applied  and  (2)  the  principal  purpose  (intended 
mainly or exclusively) to be a cosmetic product. This is exactly the same definition as can be 
found  in  Article 1 ,  1  of  the  European  Directive  76/768/EEC  of  27  July  1976
13  on  the 
Approximation of the Laws of the Member States relating to Cosmetic Products.  
In  the  1970s  the  EU  Member  States  decided  to  harmonize  their  legislation  on 
cosmetics. Free circulation of cosmetics in the EU would finally be possible.
14 The Cosmetics 
Directive  was  born.  Nonetheless,  this  directive  was  recently  repealed  by  Regulation 
1223/2009  of  30  November  2009  on  Cosmetic  Products,
15  effective  July  11,  2013.
16  A 
Regulation is a stronger legislative instrument that makes it possible to impose clear and 
detailed rules that are the same in all Member States and are implemented at the same time in 
the entire Community.
17 Article 2, § 1 (a) of the Cosmetics Regulation will define cosmetics 
in the future but the meaning stayed undifferentiated. The intent or principal purpose refers to 
the presentation of a product from the point of view of a reasonably well-informed consumer. 
This will be assessed on a case-by-case basis.
18 A cream used on the face to moisturize the 
skin for the purpose of reducing the appearance of wrinkles, in this case by influencing the 
                                                 
13 1976 O.J. (L 262) 169 [hereinafter Comsetics Directive]. 
14 1 EUROPEAN COMMISSION, ENTERPRISE DIRECTORATE-GENERAL PHARMACEUTICALS AND COSMETICS,  THE 
RULES GOVERNING COSMETIC PRODUCTS IN THE EUROPEAN 1, 3 (1999), 
http://www.leffingwell.com/cosmetics/vol_1en.pdf. 
15 2009 O.J. (L 342) 59 [hereinafter Cosmetics Regulation]. This regulation will come into force on July 11, 
2013 with some exceptions that came into force earlier. 
16 With the exception of art. 4b which is repealed with effect from 1 December 2010, see art. 38 Cosmetics 
Regulation. 
17 Recital (2) to the Cosmetics Regulation. 
18 MANUAL ON THE SCOPE OF APPLICATION OF THE COSMETICS 76/768/EEC (ART. 1(1) COSMETICS DIRECTIVE) 
1, 11 (6
th ed. 2010), 
http://ec.europa.eu/consumers/sectors/cosmetics/files/doc/manual_borderlines_version06_en.pdf [hereinafter 
MANUAL].   6 
skin stem cells, has as its principle purpose to change the appearance or protect the skin, or to 
keep it in good condition. Therefore it seems to be a cosmetic. 
Categorizing  cosmetics,  however,  is  not  that  easy.  Our  cream  could  be  called  a 
“borderline product.”
19 It might fall both within the definition of a cosmetic and a medicinal 
product.  
The Belgian Law of 25 March 1964 on Medicinal Products uses an identical definition 
of medicinal products
20 as the European Directive 2001/83/EC of 6 November 2001 on the 
Community Code relating to Medicinal Products for Human Use:
21 
 
“(a) Any substance or combination of substances presented as having properties for treating or 
preventing disease in human beings; or 
  (b) Any substance or combination of substances which may be used in or administered to 
human beings either with a view to restoring, correcting or modifying physiological functions 
by  exerting  a  pharmacological
22,  immunological
23  or  metabolic
24  action,  or  to  making  a 
medical diagnosis.” 
 
                                                 
19 Recital 7 to European Directive 2001/83/EC of 6 November 2001 on the Community Code relating to 
Medicinal Products for Human Use, 2001 O.J. (L 311) 67, mentions « so called borderline products». 
20 Art. 1, 1) a Wet op de geneesmiddelen [Law on Medicinal Products] of March 25, 1964, BELGISCH 
STAATSBLAD [B.S.] [Official Gazette of Belgium], April 17, 1964, http://www.staatsblad.be: “hetzij 
fysiologische functies te herstellen, te verbeteren of te wijzigen door een farmacologisch, immunologisch of 
metabolisch effect te bewerkstelligen, hetzij om een medische diagnose te stellen” 
21 2001 O.J. (L 311) 67 [hereinafter Medicinal Products Directive]. This is defined in art. 1,
 § 2 Medicinal 
Products Directive. 
22 This means the “interaction between the molecules of the substance in question and a cellular constituent, 
usually referred to as a receptor, which either results in a direct response, or which blocks the response to another 
agent. Although not a completely reliable criterion, the presence of a dose-response correlation is indicative of a 
pharmacological effect”. See GUIDANCE DOCUMENT ON THE DEMARCATION BETWEEN THE COSMETIC PRODUCTS 
DIRECTIVE 76/768 AND THE MEDICINAL PRODUCTS DIRECTIVE 2001/83 AS AGREED BETWEEN THE COMMISSION 
SERVICES AND THE SERVICES AND THE COMPETENT AUTHORITIES OF MEMBER STATES 1, 9, 
http://ec.europa.eu/consumers/sectors/cosmetics/files/doc/guidance_doc_cosm-medicinal_en.pdf 
23 This means the action in or on the body by stimulation and/or mobilisation of cells and/or products involved in 
a specific immune reaction. See id. 
24 This refers to the action which involves an alteration, including stopping, starting or changing the speed of the 
normal chemical processes participating in, and available for, normal body function. The fact that a product is 
metabolised by the human body does not necessarily mean that the substance contained in the product has a 
metabolic action upon the body. See id.   7 
A product can be a medicinal product “by virtue of its presentation” (that is, presented 
or promoted as having properties for treating or preventing disease in human beings) or “by 
virtue of function” (may be used in or administered to human beings either with a view to 
restoring,  correcting  or  modifying  physiological  functions  by  exerting  a  pharmacological, 
immunological or metabolic action, or to making a medical diagnosis). 
25   
For example, if the manufacturer claims that the cream will influence the stem cells in 
the skin in order to protect the skin from getting older, this would not sufficiently meet the 
definition of “medicinal product.”
26 The following claims on Amatokin Emulsion’s website 
will therefore not change the product’s classification on their own “the peptide ‘jump starts’ 
adult skin stem cells to produce new skin cells” or “research shows that as polypeptide #153 
is introduced to stem cells, an increase in cell division and thus the production of new skin 
cells  occurs”,  etc.
27    The  cream  is  not  presented  as  treating  or  preventing  disease  and 
therefore cannot be a drug by virtue of its presentation.  
The cream can nevertheless be a medicine “by virtue of function” as it may be used in 
people  in  order  to  modify  physiological  functions  in  a  more  than  insignificant  way
28  by 
exerting a pharmacological action. This does not need to be the principal purpose like for 
cosmetics. A product which reduces cellulite for example may be a medicinal product by 
virtue of function.
29 However, many products that are considered cosmetics modify in fact 
also physiological functions. Every moisturizing cream will affect the skin cells by adding 
water to the cells. These products must exercise some effect on somatic skin cells, otherwise 
                                                 
25 MANUAL, supra note 18, at 16.  
26 The Belgian Federal medicines and Health Products Agency listed some claims that do not make a cosmetic a 
drug by presentation. See http://www.fagg-
afmps.be/nl/binaries/09H002%20positieve%20lijst%20Humaan_tcm290-117288.pdf 
27 http://amatokinstore.com/index.php 
28 Case C-112/89, “Upjohn“, 1991 E.C.R. I-1703. 
29 MANUAL, supra note 18, at 19.    8 
they are useless.
30 All these are however regarded as cosmetics.
31 This has also been made 
clear through Article 7a, § 1, g of the Cosmetics Directive that states hat the manufacturer of a 
cosmetic  needs  to  give  the  competent  authority  information  on  the  “proof  of  the  effect 
claimed for the cosmetic product, where justified by the nature of the effect or product”. 
Article 11, § 2 d of the Cosmetics Regulation stipulates that the “product information file 
shall contain where justified by the nature or the effect of the cosmetic product, proof of the 
effect claimed for the cosmetic product”. Having an effect on the human body is undoubtedly 
not enough to qualify as a drug. The product has to significantly affect metabolism in order to 
modify the way in which the body functions.
 32 
If a cream can affect metabolism, it is a medicinal product. Many factors will be 
considered  in  making  this  determination,  such  as  absorption,  concentration,  route  of 
administration, frequency of application, application site, and the degree of penetration.
33 In 
addition, the risk to health is an autonomous factor that must be taken into consideration.
34 
The fact that the same substance is also present in medicinal products as an active ingredient 
is not decisive. Nevertheless, this may be an indicator of pharmacological, immunological or 
metabolic action of the substance.
35 
If  the  product  is  categorized  as  a  medicinal  product,  then  it  will  be  exclusively 
regulated by the laws pertaining to medicinal products. This is called the principle of non-
cumulation.
36  Therefore,  a  cream  that  actually  affects  the  stem  cells  in  the  body  could 
                                                 
30 GUIDANCE DOCUMENT ON THE DEMARCATION BETWEEN THE COSMETIC PRODUCTS DIRECTIVE 76/768 AND THE 
MEDICINAL PRODUCTS DIRECTIVE 2001/83 AS AGREED BETWEEN THE COMMISSION SERVICES AND THE SERVICES 
AND THE COMPETENT AUTHORITIES OF MEMBER STATES 1,  7,  
31 Recital (7) to the Cosmetics Regulation. 
32 Case C-1121/89, “Upjohn“, 1991 E.C.R. I-1703, para 21-22. Affirmed in C-150/00, “Vitamines”, 2004 E.C.R. 
I-03887, para 65. 
33 MANUAL, supra note 18, at 16. 
34 C-211/03, C-211/03, C-299/03 to C 318/03 HLH Warenvertriebs GmbH, Orthica BC v Federal 
Republic of Germany, 2005 E.C.R. I-05141, para 53.  
35 MANUAL, supra note 18, at 16. 
36 This principle is established by the European Court of Justice in Case C-1121/89, “Upjohn“, 1991 E.C.R. I-
1703. It is now part of art. 2 (2) Medicinal Products Directive. TREVOR COOK, PHARMACEUTICALS 
BIOTECHNOLOGY AND THE LAW 301-304 (2009).   9 
possibly be considered a drug by virtue of function, even if not by virtue of presentation. It is 
important  to  mention  that  only  the  European  Court  of  Justice  can  give  an  authoritative 
interpretation of EU law. This Court and national competent authorities determine on a case-
by-case basis whether a product falls within the scope of the Cosmetics Directive or the 
Medicinal Products Directive.
37 The question remains whether these creams have the potential 
to affect metabolism. In case they do not have these proprieties then the product falls only 
within the definition of a cosmetic.
38 
 
In short, under European law product claims are decisive in determining whether a 
product falls within the scope of the drug regulation. This is however only the case if the 
product  is  expressly  indicated  or  recommended  as  having  therapeutic  or  prophylactic 
properties, regardless whether the product has a known therapeutic effect.
39 A claim that the 
cream will influence stem cells in the skin is not enough to consider it a medicinal product. 
The real properties are decisive in classifying a product as a drug: does the cream modify the 
physiological  function  of  the  skin?  Once  a  product  is  categorized  as  a  drug,  the  product 
cannot also be a cosmetic, and vice versa. For cosmetics the principle purpose of the product 
determines whether it is a cosmetic or not. This refers to the presentation of the cream and the 
intent  of  the  manufacturer  and  is  evaluated  considering  the  reasonably  well-informed 
consumer. 
 
 
 
 
                                                 
37 MANUAL, supra note 18, at 2. 
38 This can make the product misbranded, see infra.. 
39 C-219/91, “Wilhelmus Ter Voort”, 1992 E.C.R. I-5485, para. 18 and  C-227/82, “Van Bennekom”, 1983 
E.C.R. 3883, para 18, both with regard to the former, slightly different-worded definition “any substance or 
combination of substances presented for treating or preventing disease in human beings or animals”.   10 
    (2) The United States’ Classification 
FDA acquired authority over cosmetics in 1938 through the Federal Food, Drug, and 
Cosmetic Act (FD&C Act).
40 The FD&C Act states that cosmetics are "articles intended to be 
rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human 
body for cleansing, beautifying, promoting attractiveness, or altering the appearance".
41 Intent 
refers to the objective intent of the person responsible for the labeling through labeling claims, 
advertisements
42, statements, Internet content, or even evidence that the vendor knows that the 
product is used for that purpose.
43 Promotional third party claims or testimonials about the 
product  are  also  seen  as  claims  that  prove  intent.
44  Any  claim  that  a  product  alters  the 
appearance or feel of the skin would also lead to classification as a cosmetic.
45 
The intended use of the article thus defines the category in both Belgium and the EU. 
Skin  moisturizers  fall  under  this  definition  as  does  any  material  intended  for  use  as  a 
component of a cosmetic product.
46  
                                                 
40 Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301 et seq. 
41 FD&C Act, § 201 (i), 21 U.S.C. § 321.  
42 Advertisements itself are also regulated. For this paper I however will not discuss them in detail. Art. 87 of 
Medicinal Products Directive (which repealed Council Directive 92/28/EEC of 31 March 1992 on the 
advertising of medicinal products for human use 1992, O.J. (L 113) 13–18) prohibits advertising of medicinal 
products for which no marketing authorizations has been granted and art. 88 prohibits ads for the general public 
for prescription-only medicinal products. (See e.g. COOK, supra note 36, at 312.) Belgium implemented this in its 
Law on Medicinal Products. Direct-to-consumer ads are therefore not allowed in the EU. 
The Federal Trade Commission Act (FTCA) enforced by the Federal Trade Commission (FTC) covers unfair or 
deceptive practices (15 U.S.C. § 5) in advertisements on cosmetics
42 and OTC products. Prescription drug ads 
are regulated by FDA. Ads are not only printed but also on TV and the internet. (See e.g. Peter Barton Hutt, 
Richard A. Merrill, Lewis A. Grossman, Food and Drug Law, Cases and Materials 809 (2007); Wen Schroeder, 
Cosmeceutical (Antiaging) Products: Advertising Rules and Claims Substantiation, in 2 GLOBAL REGULATORY 
ISSUES FOR THE COSMETICS INDUSTRY 121, 134 (Karl Lintner ed., 2009) 
43 21 C.F.R. §  201.128. Also consumer perception because of the product’s reputation and ingredients with a 
well known therapeutic use can establish the necessary intent for a drug. See e.g. Peter Barton Hutt, The Legal 
distinction in the United States between a cosmetic and a drug, in COSMECEUTICALS 223 (Peter Elsner & 
Howard I. Maibach eds., 2000). 
44 See e.g., United States v. Vital Health Products, Ltd., 786 F. Supp. 761, 776 (E.D. 
Wis. 1992), aff'd, 985 F.2d 563 (7th Cir. 1993). 
45 Repeated in United States v. “Sudden Change,” 288 F. Supp. 29 (E.D.N.Y. 1968). This case was however 
reversed because the claim was not only about altering the appearance. See infra note 56; Hutt, supra note 43, at 
232. 
46 Is it a Cosmetic, a Drug, or Both?, 
http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/ucm074201.htm   11 
Inspired by the European situation, we also want to look into the regulation of drugs 
under U.S. law. The FD&C Act defines drugs as "articles intended for use in the diagnosis, 
cure, mitigation, treatment, or prevention of disease" and "articles (other than food) intended 
to affect the structure or any function of the body of man or other animals".
47 The intent is 
defined in the same way as for cosmetics.
48 For example a claim that a product revitalizes 
cells, although marketed as a cosmetic, will establish the intended use to be a drug.
49 That is 
not a superficial effect anymore. Consumer expectations play a role too: although a fluoride 
toothpaste  manufacturer  only  claimed  that  the  toothpaste  keeps  teeth  attractive,  a  typical 
cosmetic claim, the intended use is implied by the known effects of the ingredients of the 
product.
50 Here we see an important difference compared to the European regulation. In the 
definition for drugs in the U.S., “intent” plays an important role, whereas Europe focuses 
more  on  the  proprieties  of  the  products  themselves,  unless  the  product  is  represented  as 
having  therapeutic  or  prophylactic  properties  (“may  be  used…”  in  Europe  compared  to 
“intended to use…” in U.S.). 
Products can be regulated as both cosmetics and as drugs if they have more than one 
intended use.
51 As mentioned before, this is not possible in Europe where the non-cumulation 
rule  applies.  A  moisturizer  for  example  is  intended  to  alter  the  appearance,  promoting 
attractiveness or beautifying. It is therefore a cosmetic. If the manufacturer claims the product 
will affect the structure or function of the skin in removing the wrinkles, the cream becomes a 
drug. For cosmetics only superficial effects are allowed.
52 If this is the case, the requirements 
for both cosmetics and drugs have to be fulfilled. In the popular literature these products are 
sometimes  called  “cosmeceuticals”:  a  combination  of  “cosmetics”  and  “pharmaceuticals.” 
                                                 
47 FD&C Act, § 201(g)(1): “Also articles recognized in the official United States Pharmacopoeia, official 
Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of 
them”, are considered drugs. 
48 See Senate report: S. REP. NO. 361, 74th Cong., 1st Sess. § 201 (1935). 
49  Is it a Cosmetic, a Drug, or Both?, supra note 46.  
50 Jacqueline A. Greff, Regulation of cosmetics that are also drugs, 51 FOOD & DRUG L.J. 243, 255 (1996). 
51 Hutt, supra note 43, at 223; See also e.g. Is it a Cosmetic, a Drug, or Both?, supra note 46.  
52 Schroeder, supra note 42, at 126.    12 
This is nonetheless not a term recognized by the FD&C Act.
53 Today it has been made clear 
by  court  decisions  and  FDA’s  interpreting  materials  that  for  example  a  lip  softener  is  a 
cosmetic but a lip balm for chapped lips is also a drug; a skin moisturizer is a cosmetic, but a 
wrinkle  remover  is  a  (non-prescription
54)  drug  as  well;  a  deodorant  is  a  cosmetic  but  an 
antiperspirant is a drug.
 55 
The wrinkle remover cases of the 1960s provide some great examples.
56 Claims of a 
facial cream like “face-lift without surgery” and “super-active” were considered to be drug 
claims
57 like “restructures and repairs skin”
58. Claims are often not that clear and many factors 
will be taken into account such as the overall impression of the advertisement.
59 In 1987 FDA 
issued warning letters to firms saying that “cell recovery”, “cell repair”, “increased collagen 
production”, “restructuring the deepest epidermal layers” were all drug claims.
60  
On March 1, 2011 Jaba Labs received a warning letter by FDA. StemCellin Intensive 
Emulsion  and  StemCellin  Deep  Wrinkle  Serum  StemCellin®  are  both  facial  creams  that 
claimed on their website to “activate your own skin stem cells”, “delays deterioration of 
essential  skin  cells”,  “reverses  chronological  aging”,  etc.  FDA  stated  that  the  creams  are 
therefore “promoted for uses that cause them to be drugs under section 201(g)(1)(C) of the 
Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(C)].”  The claims 
establish that these products are drugs because they are structure/function claims.
61 
 
                                                 
53 Hutt, supra note 43, at 223. 
54 See infra. 
55 For more examples see Hutt, supra note 43, at 228; Schroeder, supra note 42, at 131.   
56 United States v. “Line Away,” 284 F. Supp. 107 (D. Del. 1968), aff'd, 415 F.2d 369 (3d Cir. 1969); 
United States v. “Sudden Change,” 288 F. Supp. 29 (E.D.N.Y. 1968), rev'd, 409 F.2d 734 (2d Cir. 1969); United 
States v. “Helena Curtis Magic Secret,” 331 F. Supp. 912 (D. Md. 1971). 
57 United States v. “Sudden Change,” 409 F.2d at 742. (2d Cir. 1969). 
58 Estee Lauder, 727 F. Supp. 1. 
59 Greff, supra note 50, at 269. 
60 Gary L. Yingling & Michael A. Swit, Cosmetic Regulation, in FOOD AND DRUG LAW 366 (Food & Drug Law 
Inst. ed., 1991). 
61 Warning letter FDA to JABA LABS, March 1, 2011, 
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm246086.htm   13 
 
      (3) Conclusion 
The U.S. and Europe each classify cosmetics based on the intent. A cream that claims 
to influence stem cells in the skin could be a cosmetic in both jurisdictions, at the least as long 
as in Europe the physiological functions of the skin are not altered. In the U.S. the claim is the 
only factor that can make a cosmetic also a drug. In Europe the principle of non-cumulation 
applies which means that a product cannot be in both classes. In Europe, claims are also 
crucial for drugs but only if the claim relates to therapeutics or therapeutic or prophylactic 
properties.  Otherwise  the  function  of  the  product,  not  the  presentation  is  decisive.  This 
implies that a cream that affects stem cells in the skin would be a drug in Europe because of 
its function, regardless of the claim. In the U.S., however, this same cream would be seen as a 
cosmetic unless it were claimed that the cream affected the structure or function of the skin 
(e.g. “activate your own skin stem cells”), in which case it would also be a drug. 
 
 
 
 
 
 
 
 
 
 
 
   14 
B.  Creams Containing Human Stem Cells or Stem Cell Extracts 
 
(1) The Belgian/European Classification  
A skin moisturizer containing human stem cells or stem cell extracts is placed on 
external parts of the human body for the purpose of changing the appearance of the skin or to 
keep  the  skin  in  good  condition.  It  could  therefore  be  qualified  as  a  cosmetic  product 
according to current and future Belgian and European rules as long as it does not alter the 
function of the body. This is nevertheless not the end of the story.  
Article 2 of the Cosmetics Directive stipulates that cosmetic products “must not cause 
damage to human health when applied under normal or reasonably foreseeable conditions of 
use”. According to article 3 of the European Regulation 1223/2009 “a cosmetic product made 
available  on  the  market  shall  be  safe  for  human  health  when  used  under  normal  or 
reasonably  foreseeable  conditions  of  use”.
62  These  articles make  clear  that  cosmetics  are 
considered in Europe to be something that needs to be regulated in order to be safe. For 
thousands of years, cosmetic products only contained ingredients derived from natural sources 
such  as  plants,  minerals  and  animals.  Safety  was  not  a  significant  concern.  Nowadays 
synthetic ingredients have entered the field and increased the potential risks.
63 Fortunately, in 
practice cosmetic products only very rarely cause health hazards. This does however not mean 
that they are safe. Cosmetics may be used extensively for a long period of time. That is why 
Europe decided to regulate the ingredients of cosmetic products.
64 
                                                 
62 Art.2, 2° e) Royal Decree 15 October 1997 refers to data that have to be collected concerning risks for human 
health when the use of cosmetics is both under normal or reasonably foreseeable conditions. 
63 SCCNFP, SCCNFP’S NOTES OF GUIDANCE FOR TESTING OF COSMETIC INGREDIENTS AND THEIR SAFETY 
EVALUATION, 0690/03 (5
th ed. October, 20, 2003) 1, 
http://ec.europa.eu/health/archive/ph_risk/committees/sccp/documents/out242_en.pdf: these notes give guidance 
authorities and cosmetic industry for better and harmonized compliance with the Cosmetics Directive and its 
amendments. 
64 The First control of ingredients happened because of Council Directive 93/35/EEC of 14 June 1993 amending 
for the sixth time Directive 76/768/EEC on the approximation of the laws of the Member States relating to 
cosmetic products, 1993 O.J. (L 151) 32.    15 
Safety evaluation was first carried out by the Scientific Committee on Cosmetology 
(SCC).
65 In 1997 the Scientific Committee on Cosmetics and Non-Food Products Intended for 
Consumers  (SCCNFP)  was  established  by  the  Commission  Decision  97/579/EC.  The 
committee answered questions from the Commission and gave advice on cosmetics and non-
food products. The advisory guidelines promulgated by this committee were compulsory.
66 
Beginning in 2008 the Scientific Committee on Consumer Safety (SCCS) was established by 
Commission Decision 2008/721/EC of 5 September 2008. The SCCS functions as an advisory 
structure of Scientific Committees and experts in the field of consumer safety, public health 
and the environment. According to the preamble to the European Regulation 1223/2009 (62) 
the Commission has to be assisted by the SCCS, an independent risk assessment body. The 
SCCS is responsible for reviewing ingredients and assessing conditions for safe use. The 
results of these reviews are subsequently published. 
 
Is a cream with stem cells or stem cell extracts on the ingredients list safe? Both the 
Belgian Royal Decree
67 and the Cosmetics Directive (and the Cosmetics Regulation)
68 which 
will replace the Directive after July 11, 2013 state that “cells, tissues or products of human 
origin” are not allowed in cosmetics. This important exception has been added to the list of 
substances prohibited in cosmetics by the Eighteenth Commission Directive 95/34/EC of 10 
July 1995 adapting to technical progress Annexes II, III, VI and VII to Council Directive 
76/768/EEC on the approximation of the laws of the Member States relating to cosmetic 
products.
69 The reason for this directive is that cells, tissues or products of human origin can 
                                                 
65 The Scientific Committee on Cosmetology (SCC) was founded on 19 December 1977 by Commission 
Decision 78/45/EEC in order to assist the European commission in drawing and amending European Union 
directives and regulations on cosmetic products. See SCCNFP, OPINIONS 1997-2004, CLASSIFICATION OF 
SUBSTANCES AS INGREDIENTS OF COSMETIC PRODUCTS 3, 
http://ec.europa.eu/health/archive/ph_risk/committees/sccp/documents/out242_en.pdf 
66 Ar. 8.2. Cosmetics Directive. 
67Annex art. N2, n° 416 Royal Decree on Cosmetic Products. 
68 Annex II, List of prohibited substances in cosmetic products, n°416 Cosmetics Directive and Regulation. 
69 1995 O.J. (L 167) 19.    16 
transmit the Creutzfelt-Jakob disease, human spongiform encephalopathy, and certain virus 
diseases  such  as  human  immunodeficiency  virus  (HIV).  Given  the  state  of  scientific 
knowledge in 1995 up until now, it seemed necessary to prohibit human cells, tissues and 
other  products  in  cosmetics  under  the  “precautionary  principle.”
70  The  SCCNFP  of  the 
European Commission stated that only “substances for which data at the time of assessment 
support the conclusion that they do not pose a health hazard” may be used in cosmetics. In 
case substances are dangerous for health according to available data or the data do not justify 
the assumptions that they are safe, they cannot be used as ingredients in cosmetics. 
71 This 
was already the position of the SCC, as stated on October 4, 1994 to prohibit the use of 
human tissues and extracts in cosmetics.
72 Therefore, it appears that stem cells or stem cell 
extracts are not safe or at the least not proven to be safe for use in cosmetics. 
 
In brief, a cream containing human stem cells or products derived from human stem 
cells is considered by European authorities not safe enough to enter the market. Compliance 
with the regulation for cosmetics even does not offer enough safety. The cream is therefore 
not a cosmetic and does not need to follow the regulation pertaining to cosmetics. This of 
course does not permit manufacturers to market these products free from control. Creams with 
stem cells/extracts may be considered medicinal products. Stem cells in a cream do not cause 
                                                 
70 Preamble Eighteenth Commission Directive 95/34/EC of 10 July 1995 adapting to technical progress Annexes 
II, III, VI and VII to Council Directive 76/768/EEC on the approximation of the laws of the Member States 
relating to cosmetic products. The principle implies that when “there are reasonable grounds for concern for the 
possibility of adverse effects but scientific uncertainty persists, provisional risk management measures based on 
a broad cost/benefit analysis whereby priority will be given to human health and the environment” may be 
adopted, See ELIZABETH, JUDITH JONES & RENE VON SCHOMBERG, IMPLEMENTING THE PRECAUTIONARY 
PRINCIPLE: PERSPECTIVES AND PROSPECTS (2006). 
71 SCCNFP, OPINIONS 1997-2004, SCIENTIFIC COMMITTEE ON COSMETIC PRODUCTS AND NON-FOOD PRODUCTS 
INTENDED FOR CONSUMERS - THE CLASSIFICATION OF SUBSTANCES ADOPTED BY THE SCCNFP DURING THE 11TH 
PLENARY MEETING OF 17 FEBRUARY 2000, 
http://ec.europa.eu/health/scientific_committees/consumer_safety/opinions/sccnfp_opinions_97_04/sccp_out110
_en.htm 
72 SCCNFP, OPINIONS 1997-2004, OPINION CONCERNING AMINO ACIDS OBTAINED BY HYDROLYSIS OF HUMAN 
HAIR, June 28, 2000, 
http://ec.europa.eu/health/scientific_committees/consumer_safety/opinions/sccnfp_opinions_97_04/sccp_out122
_en.htm   17 
problems this time. Substances in a drug can be of human origin.
73 If a stem cell cream 
against wrinkles for anti-ageing can be used to correct or modify physiological functions by 
exerting a pharmacological action, it might be classified as a medicinal product in Belgium 
and  Europe.  This  is  only  in  case  the  cream  has  a  significant  effect  on  the  physiological 
functions of the body. If the cream works as a normal cream it will not be a drug and it can 
therefore in my opinion not be marketed in Europe. 
It is now interesting to see how a cream containing stem cells will be classified in the 
U.S. 
 
(2) The United States’ Classification  
As mentioned above, the U.S. uses the “intent” requirement to qualify cosmetics, as 
does Europe. Facial creams are therefore usually cosmetics. In the U.S. FDA only prohibits 
eleven cosmetic ingredients compared to 1328 in the Cosmetics Regulation in Europe.
74 Cells 
from human origin are not in the list of prohibited substances in the U.S. At first glance there 
is therefore no reason why a cream containing stem cells/extracts from stem cells could not be 
considered a cosmetic.  
In  the  U.S.  drugs  are  classified  according  to  the  claims  made
75  whereas  Europe 
focuses  more  on  the  properties  of  the  product  itself.  This  difference  can  have  important 
consequences. 
A facial cream containing stem cell extracts will not be considered a drug in the U.S. 
as  long  as  the  manufacturer  does  not  claim  it  is  intended  to  use  in  the  diagnosis,  cure, 
mitigation, treatment, or prevention of disease or to affect the structure or any function of the 
                                                 
73 Art. 2 Law on Medicinal Products, art. 1, 3 Medicinal Products Directive. 
74 www.national-toxic-encephalopathy-foundation.org/cirpro.pdf. In the GUIDE TO INSPECTIONS OF 
COSMETIC PRODUCT MANUFACTURERS, 
http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074952.htm, FDA adds 5 more ingredients that are 
prohibited. 
75 See Senate report: S. REP. NO. 361, 74th Cong., 1st Sess. § 201 (1935).   18 
body of man or other animal. When the website of Swiss Apple Stem Cell Serum alleges that 
the product “boosts the production of human skin stem cells, protects human skin stem cells 
from  stress,  thus  decreasing  wrinkles  and  producing  younger,  fresher  looking  skin”,  this 
makes  the  product  a  drug.
76  In  Europe  as  mentioned  before,  only  if  the  cream  alters  the 
function of the body will it be considered a drug. A facial cream containing human stem cells 
or stem cell extracts, claiming to influence the existing stem cells in the skin, so that the 
existing stem cells will be activated, can be considered not only a cosmetic but also a drug in 
the U.S. based on that claim.
77 These products are then intended to affect the function of the 
body. This is the case regardless of whether there are stem cells in the cream and whether the 
cream  actually  works.  Perhaps  surprisingly,  it  is  not  the  ingredients  but  the  claims  that 
determine the applicable regulation. In reality however, FDA will often decline to classify a 
product as a drug, despite of the almost drug claim, as long as it has no drug efficacy or the 
product is proven to be safe.
78  
 
FDA bases its classification sometimes on the ingredients and sometimes on the risk 
of the product.
79 It seems indeed not logical that an ingredient that might be unsafe can be put 
in a topically-applied product as cosmetic as long as the manufacturer does not claim that it is 
a drug.
80 It is however not true that the mere use of the ingredient makes it a drug. The use of 
active pharmaceutical ingredients (APIs) can lead to the classification of a product as a drug 
when the ingredient is so closely identified with therapeutic properties that using the term in 
                                                 
76 http://www.stemcellskincare.com/Stem_Cell_Skin_Care_Serum.htm 
77 Warning letter FDA to JABA LABS, March 1, 2011, 
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm246086.htm 
78 A product can be considered safe without going through the drug procedure if it is a nonprescription drug. See 
infra.Cosmetic Products Containing Certain Hormone Ingredients: Notice of Proposed Rulemaking, 58 Fed. 
Reg. 47,611 (1993). 
79 Discussed in Greff, supra note 50, at 243. 
80 Robert P. Giovacchini, The Significance of the Over-the-Counter Drug Review with Respect to the Safety 
Considerations of Cosmetic Ingredients, 30 FOOD DRUG COSM. L.J. 223 (1975).   19 
the label or just in the ingredients list makes it a drug claim.
81 This argument was used by 
FDA for cases in which the ingredients had only drug functions or the ingredients at higher 
concentrations could only have drug effects. This is nonetheless never discussed in court. 
82 
For  example  with  cosmetics  containing  hormones,  FDA  first  defined  using  the  term 
“hormone”  as  an  implied  drug  claim.  A  new  drug  application  approval  was  therefore 
necessary, unless the hormones had been proven to be safe.
83 In the latter case the hormones 
could also be used in cosmetics without triggering regulation as a drug. 
84  
  FDA also classified some products as drugs based on the risk they cause to consumers. 
Absent promotional drug claims, a product may be deemed a drug because of actual physical 
effects.
85 This is however not always a sign of the objective intent because it is possible that 
the manufacturer decided to put the product on the market despite of the side-effect and not 
because of the drug effect. Courts will most likely not uphold this argument as it is contrary to 
the statute. 
86 Another reason according to some why this classification might not be upheld is 
that (almost) all cosmetics penetrate the skin which means they all affect the structure or 
function  of  the  body.
87  I  think  nonetheless  that  this  interpretation  is  not  convincing.  All 
cosmetics seek to create a certain effect or they would not be marketed. As long as the effect 
is superficial one could say it stays a cosmetic. If a product alters, repairs or renews the skin, 
even only temporarily, then there is a drug. This would be the case in Europe too. Claims are 
therefore not the only possibility as a criterion to classify products. For now the U.S. still uses 
the claim that the structure or function of the body is affected to make the product a drug, not 
                                                 
81 United States v. Articles of Food and Drug, 444 F. Supp. 266, 271 (E.D. Wisc. 1978).  
82 Greff, supra note 50, at 254-255. 
83 See infra. 
84 58 Fed. Reg. 47,608 and 47,611. 
85 Greff, supra note 50, at 255-256. 
86 Greff, supra note 50, at 256. 
87 Hutt, supra note 43, at 227.   20 
the effect itself. For example, a product that claims to even temporarily repair or renew skin 
would be classified as a drug.
 88 
 
 
    (3) Conclusion 
Creams  based  on  stem  cells  or  extracts  from  stem  cells  are  not  treated  the  same 
everywhere. In Europe they do not fall within the regulation of cosmetics because of safety 
risks, but they can be cosmetics in the U.S. In case there is a structure/function claim also the 
drug regulation has to be applied in the U.S. In Europe the cream can be regulated as a drug, 
but only if it has a significant effect on the physiological functions of the body. Otherwise the 
cream cannot be marketed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
88 Hutt, supra note 43, at 232. 
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II. Stem cell creams regulated 
 
A.  Regulation in Belgium/Europe 
 
A cream influencing stem cells in the skin, without containing stem cells from humans 
is a cosmetic if it does not change the function of the body. It is a medicinal product if it does 
change that function. For the latter regulation I refer to the explanation in part (2). I will 
discuss first the regulation concerning cosmetics.  
 
  (1) Creams Claiming to Influence the Stem Cells in the Skin Without Affecting the 
Function of the Skin: Cosmetics 
 
Cosmetics can only be manufactured in Belgium or imported in Belgium from outside 
of the European Union if the following criteria are met:
89 
 
1. The responsible person (the person who lets the product enter the market for the first time 
or who manufactures it) notifies the competent authority or “CA” (the Federal medicines and 
Health Products Agency in Belgium)
90 of its activities before entering the cosmetic enters the 
                                                 
89 The Royal Decree on Cosmetic Products informs us that there are four major steps in order to be sure 
cosmetics are safe.  
90 Federale Overheidsdienst Volksgezondheid, Veiligheid van de Voedselketen en Leefmilieu (FAGG/AFMPS)     22 
market. An “activity” can be, for example, information on where the dossier in point 4, infra,  
is available.
91  
The  manufacturer  in  Belgium  must  also  notify  the  CA  of  its  activities  in  Belgium  as  a 
manufacturer of the product before entering the market and must notify the CA afterwards 
annually.
92  
 
2. The labeling complies with the requirements: warnings,
93 not misleading,
94 etc.
95 
 
3. The responsible person handed over the formulas to the poison centre not less than forty-
eight hours before the product enters the market, and must do so again each time the formula 
changes.
96  
 
4. The responsible person keeps a dossier with all data on the product.
97 The following are 
among the data that have to be included in the dossier: 
  the composition of the product;  
  detailed lists of the building blocks of the product and of the  finished product; 
  the method of manufacturing; 
                                                 
91 Art. 2, 1° Belgian Royal Decree 15 October 1997 and art. 7,4 Cosmetics Directive, art. 13 Cosmetics 
Regulation asks the responsible person (manufacturer, importer, distributor, etc see art. 4) to notify the 
Commission. 
92 Art. 2, 1°bis Belgian Royal Decree 15 October 1997 and art. 7,4 Cosmetics Directive, art. 13 Cosmetics 
Regulation asks the responsible person (manufacturer, importer, distributor, etc see art. 4) to notify the 
Commission. 
93 Art. 5, §1, 3° and annex 3 and 8 Belgian Royal Decree of 15 October 1997, annexes of Cosmetics Directive 
and Regulation. 
94 Labels see art. 6, 1° and Belgian Royal Decree 15 October 1997; art. 6, 3 Cosmetics Directive; art. 20, 1 
Cosmetics Regulation. 
95 Art. 4, 1° and Belgian Royal Decree 15 October 1997; art. 2 Cosmetics Directive; art. 3 b and 19 Cosmetics 
Regulation. 
96 Art. 2, 5° Belgian Royal Decree 15 October 1997 and only in Cosmetics Regulation the responsible hands the 
information over to the commission which will inform the poison centre. 
97 Art. 2, 2° Belgian Royal Decree 15 October 1997; art. 7 a 1 Cosmetics Directive and art. 11 Cosmetics 
Regulation.    23 
  safety  control  about  the  effects  of  the  product  on  human's  health  through  risk 
assessment by a safety assessor:  as long as the cosmetic is found to be safe for use,
98 
the cream will not be rejected by the safety assessor.
99 
 
The rules explained above show that safety of cosmetics in Europe is determined by 
qualified and experienced safety assessors. Data from the UK prove that this is a quick and 
effective  assessment  and  ensures  consumer  safety.
100  This  is  combined  with  good 
manufacturing practices which need to be followed in order to manufacture cosmetics so the 
end user will not be harmed.
101 
Contrary  to  drugs  (see  infra)  which  can  only  contain  substances  listed  in  a 
compendium or ingredients that are explicitly supported,
 102  cosmetics can normally contain 
any ingredient not otherwise restricted or prohibited.
103 Even if all ingredients of a particular 
product are allowed, the final product can be unsafe and therefore will not have the required 
safety stamp and cannot be allowed to enter the market.
104 The labeling requirements are also 
different. A true premarket approval is not in use but premarket notification on the other hand 
is a requirement through which the safety assessor can reject the product as not safe.
105 In the  
very improbable case that the manufacturer decides to put the product on the market even 
though it is declared unsafe, Article 18 of the Law of 24 January 1977 on Consumer Health 
                                                 
98 Under the umbrella requirement in art. 4, 1° Royal Decree of 15 October 1997; art. 2 Cosmetics Directive and 
article 3 Cosmetics Regulation. 
99 Art. 3, §2, 1° Belgian Royal Decree of 15 October 1997; art. 7a 1 e) Cosmetics Directive; art. 10, 2 Cosmetics 
Regulation. 
100 Betton, supra note 1, at 18-19.  
101 Rudolf A. Overbeek and Roel Pekay, Restricted Substances in Consumer Products: the Challenge of Global 
Chemical Compliance, in supra note 1, at 71, 80. See for example art. 7,a, 1, C) Cosmetics Directive and art. 3, 
3° Royal Decree on Cosmetic Products. 
102 Janet Winter Blaschke, Regulatory Developments in Canada, Japan, Australia, China, and India, in supra 
note 1, at 21, 32; see e.g. art. 5 a Cosmetics Directive. 
103 Annex II prohibited, annex III restricted use of the applicable legislation. 
104 The umbrella requirement in art. 4, 1° Royal Decree of 15 October 1997, art. 2 Cosmetics Directive and 
article 3 Cosmetics Regulation. 
105 Art. 25 Cosmetics Regulation.   24 
Protection
106 will apply: the products are considered dangerous for human’s health and the 
Competent Authority can take actions to prevent the product from entering the market. The 
Competent Authority will, once on the market “require the responsible person to take all 
appropriate  measures,  including  corrective  actions  bringing  the  cosmetic  product  into 
conformity, the withdrawal of the product from the market or its recall, within an expressly 
mentioned  time  limit.”  Fines  and  imprisonment  are  also  possible  punishments  if  the 
responsible person does not comply.
107 
Where a cream falsely claims to influence the stem cells in the skin, the cream will be 
considered a cosmetic. Cosmetic products, however, may not make claims that are untrue, and 
the responsible person would therefore need to change the claim. From the moment the cream 
has a significant effect on metabolism it will be considered a drug. 
 
(2) Creams  Containing  Human  Stem  Cells  or  Stem  cell  Extracts  and 
Influencing Stem Cells in the Skin or Creams Influencing Stem Cells in the 
Skin that Affect the Function of the Skin: Drugs 
 
A stem cell cream that contains human stem cells cannot be classified as a cosmetic 
product under current European regulations. Therefore, the cream will be regulated as a drug. 
In  order  to  obtain  marketing  authorization  in  the  EU,  the  Commission  on  the 
recommendation  of  the  European  Medicines  Agency  (EMEA)  or  a  national  competent 
authority
108  (in  Belgium,  this  is  the  Federal  Medicines  and  Health  Products  Agency) 
determines  whether  to  grant  a  marketing  application  after  consideration  of  the  submitted 
                                                 
106 Wet betreffende de bescherming van de gezondheid van de gebruikers op het stuk van de voedingsmiddelen 
en andere producten [Law on Consumer Health Protection] of January 24, 1977, BELGISCH STAATSBLAD [B.S.] 
[Official Gazette of Belgium], April 8, 1977, http://www.staatsblad.be 
107 Artt. 19 and 20  Law on Consumer Health Protection.  
108 Art. 6 Medicinal Products Directive.   25 
dossier. 
109 Quality, safety and efficacy are factors that will be taken into consideration before 
market  authorization  can  be  awarded.  Article  8,  3,  (i)  shows  that  for  example  results  of 
pharmaceutical  (physico-chemical,  biological  or  microbiological)  tests,  pre-clinical 
(toxicological and pharmacological) tests and clinical trials have to be submitted. This is only 
possible after the clinical trial application is approved.
110 Irrespective of the procedure
111 that 
has to be followed, applying for marketing authorizations is a very time consuming procedure. 
Companies  creating  stem  cell  creams  will  not  try  to  enter  the  European  market  as  this 
regulation is too strict for them to be profitable. 
  There  is  also  an  ongoing  obligation  to  carry  out  post-market  surveillance,  called 
“pharmacovigilance.”
112 Inspections are part of the competent authority’s power.
113 
  If a product such as Peau Magnifique actually does what is claimed on its website, 
namely, dramatically increase skin cell renewal, this would be proof that the product is a drug 
by  virtue  of  function  if  it  were  marketed  in  Europe.
114  However,  in  most  cases  products 
cannot  live  up  to  such  unrealistic  claims.  In  that  case  a  product  will  be  classified  as  a 
cosmetic, but as a cosmetic it would not comply with all requirements, such as labels that are 
not misleading and proof of the claimed effect. The competent authority would in Europe 
therefore ask to bring the product into conformity or to withdraw the product from the market. 
A recall is another option. Otherwise fines and imprisonment are possible.
115 
 
  (3) Conclusion 
                                                 
109 SALLY SHORTHOSE, GUIDO TO EU PHARMACEUTICAL REGULATORY LAW 33 (2010), COOK, supra note 36, at 
283 et seq. 
110 http://www.pharmainfo.net/reviews/new-drug-approval-process-regulatory-view 
111 Centralized, decentralized, mutual recognition or national procedure. See SALLY SHORTHOSE, GUIDO TO EU 
PHARMACEUTICAL REGULATORY LAW 47 et seq. (2010). 
112 Artt. 21 to 29 European Regulation No. 726/2004 of the European Parliament and of the Council of 31 March 
2004 laying down Community procedures for the authorisation and supervision of medicinal products for human 
and veterinary use and establishing a European Medicines Agency, 2004 O.J. (L 136) and artt. 101 to 108 
Medicinal Products Directive.  
113 Art. 111 Medicinal Products Directive.  
114 http://www.reviveskincare.com/store/shop/Serums_Peau-Magnifique-Youth-Recruit_prod120041 
115 See supra.   26 
    The  rules  concerning  cosmetics  are  less  stringent  than  those  for  drugs  for 
which, for example, premarket authorization rather than premarket notification is necessary
116 
and only ingredients in a compendium or explicitly supported ingredients are allowed.
117 Both 
cosmetics and drugs need to comply with (different) good manufacturing practices. However, 
this does not mean that cosmetics are not regulated enough in Europe. A cream that does not 
contain stem cells but claims to influence stem cells will be required to comply with cosmetic 
rules if the claim is untrue, but possibly the drug rules would apply if the claim were true. A 
false  cosmetic  claim  will  not  be  allowed  and  the  claim  needs  to  be  changed.  A  cream 
containing  stem  cells  will  always  need  to  follow  the  more  stringent  drug  rules  of  tests 
followed by marketing application. In most cases, this will not be profitable because, first, it is 
a time consuming procedure to get approval, and second, the cream needs to be effective (the 
claim needs to be true).  In most cases, this means that the cream will probably not be put on 
the market.  
 
B. Regulation in the United States 
 
A cream with human stem cells as ingredients or a cream that influences the stem cells 
in the skin are regulated in the same way as long as they claim to have the same effects. First 
I’ll discuss the cream when there is not a structure/function claim. Then I’ll discuss it when 
there is a structure/function claim. 
  
(1) Creams Influencing Stem Cells in the Skin and/or Containing Human Stem 
Cells or Stem Cell Extracts Without Structure/Function Claim: Cosmetics 
 
                                                 
116 Betton, supra note 1, at 18-19.  
117 Blaschke, supra note 102, at 32. 
 See e.g. art. 5 a Cosmetics Directive.   27 
The  “Colors  and  Cosmetics”  division  within  FDA’s  Center  for  Food  Safety  and 
Applied Nutrition (CFSAN) regulates cosmetics.
118 This makes cosmetics the only product of 
significance under FDA’s authority without a center of its own in FDA.
119 It is therefore no 
surprise that cosmetics are regulated much more leniently than any other product under its 
authority.
120  
Cosmetic  products  and  ingredients  (except  for  color  additives)  do  not  need  to  get 
FDA’s premarket approval (which is the case for most drugs see infra) and are not subject to 
safety or efficacy testing, or good manufacturing practices (although there was in the past an 
initiative to create good manufacturing practices (GMPs) for cosmetics, this idea has never 
been acted upon
121).
122 The “Safe Cosmetics Act of 2010”
123 would have required cosmetic 
companies to register the company and its products with FDA, fully disclose ingredients in 
products and share safety data, etc. However, the bill never became law. 
Safety  is  now  still  only  assured  through  the  rules  concerning  adulteration  and 
misbranding  in  the  FD&C  Act,  the  label  requirements  in  the  FPLA  Act  and  some 
administrative regulations. A warning label is mandatory in case the safety is not adequately 
substantiated.
124 This scheme works well according to some, because cosmetics are by nature 
generally low risk and because of industry self-regulation.
125 Moreover, FDA is not equipped 
to investigate all potential situations but must allocate its resources in a way that focuses on 
the most life-threatening public health issues. Cosmetics often do not cause serious adverse 
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effects compared to food, drugs or medical devices.
126 Cosmetics are only regulated through 
the  Center  for  Food  Safety  and  Applied  Nutrition.
127  In  case  there  is  a  safety  problem 
concerning cosmetics, it is not predictable when they will react.
128 
The FD&C Act prohibits both adulteration, which takes into account the composition 
of the product and the container and how it is manufactured and shipped (sec. 601), and 
misbranding, which focuses on the representation of the product (sec. 602) for products in 
interstate commerce (sec. 301).  
The introduction or delivery for introduction into interstate commerce of any cosmetic 
that is adulterated or misbranded is prohibited. The adulteration or misbranding in interstate 
commerce itself is not allowed. The receipt in interstate commerce of such a cosmetic and the 
delivery or proffered delivery thereof for pay or otherwise is also prohibited. Not only is it 
prohibited to engage in any of the above actions but also the causing of these actions is 
prohibited. (sec. 301)  
Interstate commerce is a requirement that is almost always fulfilled as it applies to all 
different steps in a product’s manufacture, packaging and distribution. Although there are 
certain exemptions,
129 factors such as these generally cause the requirements of the FD&C 
Act to apply to your products.
130 
A cosmetic is adulterated if it:
131 
 
•  contains poisonous or deleterious substance that may render it injurious to users; (a) 
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•  contains a filthy, putrid, or decomposed substance; (b) 
•  has been prepared, packed, or held under insanitary conditions; (c)  
•  contains an unapproved color additive (not applicable to hair dyers) (d) or  
•  is in a container composed of a poisonous or deleterious substance that may render it 
injurious (e). 
 
Let us take a closer look at Lifeline’s skin serums.
132 Recall that these creams contain 
stem  cells  extracts  derived  from  human  oocytes.  They  could  therefore  be  considered 
adulterated  in  the  U.S.  because  stem  cells  of  human  origin  are  considered  deleterious 
substances  that  may  render  the  cream  dangerous  for  consumer’s  health.  The  European 
regulation for example made clear that cells from human origin are prohibited. One could 
therefore conclude they are not safe. This is nevertheless not always true.  
On the one hand, many chemicals listed in the Annexes to the European regulations will 
never be used in cosmetics, such as aircraft fuel. This argument is nonetheless not applicable 
here because the stem cell extracts are used in cosmetics. On the other hand the chance that a 
product will truly be absorbed by the skin and cause harm is not high. The epidermis is 
waterproof and relatively non-permeable (if intact), therefore the formulation of the drug is 
very important to reach the deeper layers and pass the epidermal layer.
133 In addition, experts 
state that growth factors and enzymes are notoriously temperature-sensitive. In order to work 
“ingredients would have to remain stable for weeks or months at room temperature, get past 
the epidermal layer, go into the right cells, and exert the proper stimulation once reaching 
                                                 
132 http://www.lifelineskincare.com/ 
133 If the cream would contain full stem cells, the next problem is then keeping the stem cells at their place. For 
this it relies on cell signaling and various properties of the tissue such as stiffness. Another problem would be the 
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cell extracts in the end. See e.g. Dennis E. Discher, Paul Janmey & Yu-li Wang, Tissue Cells Feel and Respond 
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their destination”.
134 If all that would occur, the cream would be an adulterated cosmetic. If 
these properties are in addition claimed, the product would become a drug, with all regulatory 
consequences.
135 The chance that Lifeline’s skin serums would be considered an adulterated 
cosmetic because they contain human stem cell extracts seems therefore negligible. Important 
however in this discussion is a study carried out by the Cosmetic Ingredient Expert Panel on 
human products in cosmetics.
 136  “Different materials called Human Placental Extracts and 
Placental  Extracts,  assumed  to  contain  estrogenic  hormones  or  other  biologically  active 
substances,  are  not  recognized  as  cosmetic  ingredients,  even  though  the  use  of  these 
ingredients in cosmetics has been reported to the Food and Drug Administration (FDA).”
 137 
The conclusion of the research was that the available data were insufficient to support safety 
for use in cosmetics.
138 In short it seems that these serums are adulterated cosmetics and FDA 
could act upon it (see infra). However FDA does not act. In my opinion this means that 
change is clearly necessary. I have another argument to support this. 
The same cream, but this is even true without stem cells as ingredients, can also be 
adulterated if the substance that would influence the stem cells in the skin is not safe. If the 
cream really works and influences skin stem cells, this actually influences the structure or 
function of the skin and therefore is more hazardous than a normal cosmetic. Although no 
drug claim was made in my example, I think that it would be better for consumer’s safety if 
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the drug regulation would apply, which is in Europe the case. As a practical result this would 
probably drive these manufacturers away from the market.  
 
 
 
 
Cosmetics are on the other hand misbranded if:
139 
 
•  its labeling is false or misleading (a); 
•  its  labeling  fails  to  contain  the  name  and  address  of  the  manufacturer,  packer,  or 
distributor and an accurate statement of the quantity of its contents (b);  
•  its labeling fails to include any required information (c); 
•  its container is made, formed, or filled so as to be misleading (d); 
•  its packaging or labeling violates the Poison Prevention Packaging Act of 1970 (f) or 
•  it is a color additive that violates the packaging and labeling requirements under section 
721. (e) 
 
A cosmetic is misbranded when the label does not bear the required information and 
warnings or is false and misleading.
140 The terms label and labeling are the same for different 
products under FDA’s authority: labeling refers to “all labels and other written, printed, or 
graphic matter upon any article or any of its containers or wrappers, or accompanying such 
article”. A label is “the display of written, printed, or graphic matter upon any article or any of 
its containers or wrappers, or accompanying such article”.
141 Any promotional material, even 
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on the Internet, can be considered a label.
142 A label is false or misleading when the claim 
contained therein is false or misleading. 
143 If our cream, however ,falsely states that it can 
influence stem cells in the skin, it can be construed as misbranded but the misbranding l arises 
under the drug regulation, not the cosmetics regulation (see infra). 
 
The Fair Packaging and Labeling Act (FPLA)
144 is another statute through which the  
FDA can regulate cosmetics, including and our cream.
145 The FPLA requires a full ingredient 
declaration in order to enable consumers to make informed purchases. In the event a cosmetic 
violates the FPLA requirements, it will also be considered misbranded under the FD&C Act. 
146  
 
In addition to the above statutes, there are also a wide variety of applicable regulations.
147 
For example, some ingredients are prohibited (see supra). All other ingredients can be used as 
long as the finished cosmetic is safe, the label is in compliance with regulations and the 
ingredient does not cause the cosmetic to be adulterated or misbranded.
148 A cosmetic that is 
shown to be unsafe, without a warning on the label that the safety of the product has not been 
determined, can be regarded as misbranded.
149 
 
FDA is not the only actor regulating cosmetics; the industry actively uses self-regulation 
too.  For  example,  the  cosmetic  industry  is  not  only  controlled  by  FDA  but  also  by  the 
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Personal  Care  Products  Council  (PCPC),  which  was  previously  the  trade  association, 
Cosmetic, Toiletry and Fragrance Association (CTFA). CTFA was established in 1976 by the 
voluntary  Cosmetic  Ingredient  Review  (CIR)  in  order  to  control  the  safety  of  cosmetics' 
ingredients.
150  CIR  Expert  Panel  results  are  published  in  the  International  Journal  of 
Toxicology and on the CIR website. This procedure is comparable to the European SCCS, 
although  the  latter  is  mandatory.  CIR’s  findings  are  not  binding.
  151  An  example  is  the 
cosmetic ingredients compendium of the CIR in 2009. As highlighted earlier, human placental 
protein, human placental enzymes, human placental lipids and human umbilical extract were 
classified as “insufficient data to support safety”.
152 Like Lifeline’s skin serums, discussed 
above, a product like Stemixx which contains human umbilical stem cell extracts is therefore 
not proven to be safe. Nevertheless, the product is sold in the U.S. as CIR’s reports are not 
compulsory for FDA to follow.  
Similarly,  registration  of  establishments  is  not  required  but  possible  (Voluntary 
Cosmetic Registration Program
153 21 C.F.R. 710 and 720); nor is filing data on ingredients or 
adverse events related to cosmetics.  
On the one hand, this does not mean FDA has no power at all to react. FDA can take 
regulatory action against an adulterated or misbranded cosmetic. FDA can inspect cosmetic 
manufacturing facilities in order to find out whether cosmetics are adulterated or misbranded 
under the FD&C Act or FPLA.
 154 FDA collects samples during plant inspections, follow-up 
to  complaints  of  adverse  reactions  (CAERS),  etc.  Research  on  cosmetic  products  and 
                                                 
150 Greff, supra note 50, at 245-246.  
151 Greff, supra note 50, at 246. 
152 http://www.cir-safety.org/staff_files/PublicationsListDec2009.pdf 
153 Voluntary Registration of Cosmetic Product Establishments, 39 Fed. Reg. 10,059 (1974) (codified at 21 
C.F.R. § 710); Voluntary Filing of Cosmetic Product Ingredient and Cosmetic Raw Material Composition 
Statements, 39 Fed. Reg. 10,060 (1974) (codified at 21 C.F.R. § 720); Voluntary Filing of Cosmetic Product 
Experiences, 39 Fed. Reg. 10,062 (1974) (codified at 21 C.F.R. § 730). 
154 Voluntary Registration of Cosmetic Product Establishments, 39 Fed. Reg. 10,059 (1974) (codified at 21 
C.F.R. § 710); Voluntary Filing of Cosmetic Product Ingredient and Cosmetic Raw Material Composition 
Statements, 39 Fed. Reg. 10,060 (1974) (codified at 21 C.F.R. § 720); Voluntary Filing of Cosmetic Product 
Experiences, 39 Fed. Reg. 10,062 (1974) (codified at 21 C.F.R. § 730).   34 
ingredients is also part of FDA’s actions. Moreover, from the moment these products enter the 
market, enforcement actions are still possible.
155 Through the Department of Justice in the 
federal court system, FDA can even try to remove these cosmetics from the market. In order 
to prevent continued shipping of the product, a restraining order from a district court is also 
useful. These products can be seized as well. Criminal action is another possibility in the fight 
against a person who violates the law.
156 Another incentive to comply is that the industry too 
benefits from the continued sale of safe products.  
On the other hand, FDA does not have the power to recall an unsafe cosmetic. A 
manufacturer can decide to opt for market withdrawal or recall (in instances of a violation of 
the FD&C Act).
157 Companies are also not required to register their cosmetic establishments, 
file data on ingredients or report cosmetic-related injuries to FDA (like, for example, as is 
necessary for nonprescription drugs, see infra). It is important to note that FDA’s decision to 
take  regulatory  actions  is  “based  upon  agency  priorities,  consistent  with  public  health 
concerns and available resources”.
158 FDA enforcement therefore is not that common in this 
area of law and cosmetics are often not a priority.
159 Even with scarce resources, preventive 
actions are, in my opinion, preferable and cheaper than reacting after the fact.  
Today, Europe and the U.S. ensure a bilateral cooperation through a confidentiality 
agreement  entered  into  on  2  July  2007,  which    enables  them  to  exchange  confidential 
information about the safety of cosmetics such as post-marketing data; and the multilateral 
cooperation  through  a  regulatory  dialogue  called  "International  Cooperation  on  Cosmetic 
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Regulation" (ICCR) with Japan and Canada as well
160. I think the time has come to harmonize 
the regulation of cosmetics. At this time, if our cream is considered a pure cosmetic, the 
regulation is clearly less stringent than in the European Union where the cream containing 
stem  cells  and  the  cream  influencing  the  stem  cells  in  the  skin  would  follow  the  drug 
regulation. Even the cosmetic rules itself are more lenient in the US than in Europe. There is 
neither mandatory premarket notification nor safety or efficacy testing: there is no safety 
control laid out by FDA, no adverse events need to be filed and the companies do not need to 
be registered. FDA could however react against an unsafe cosmetic when it is adulterated or 
misbranded but FDA’s policy does not make cosmetics their priority and therefore FDA often 
does not act.  
 
(2) Creams Influencing Stem cells in the Skin and/or Containing Human Stem 
Cells or Stem Cell Extracts, Both With Structure/Function Claim: Cosmetic 
and Drug
161 
 
When the cream is both a cosmetic and a drug, not only the cosmetic but also the drug 
requirements  have  to  be  fulfilled.  This  is  important  as  the  requirements  for  these  two 
categories of products differ substantially in the U.S.
162  
  
In addition to the elements listed for cosmetics, a drug is adulterated if:
163  
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•  it has not been manufactured, processed, packed, and held in conformity with current 
good manufacturing practices; (a) (2) (B) 
•  its strength, quality, or purity does not meet compendial standards; (b) 
•  its strength, quality, or purity does not meet purported standards (c) or 
•  it has been mixed or packed with any substance that reduces its quality of strength. (d) 
 
 
 
In addition to the factors I summed up for cosmetics, a drug product is misbranded if:
164 
•  it  is  not  labeled  with  the  established  name  of  the  drug,  the  active  ingredient(s), 
adequate directions for use, and adequate warnings (e);  
•  it is manufactured, prepared, propagated, compounded, or processed in an unregistered 
establishment (o); 
•  it is a nonprescription drug marketed in the U.S. and on the label there is no domestic 
address or domestic phone number to send a report of serious adverse event to (x) or 
•  the  responsible  person  (who  submitted  the  drug  application)  fails  to  comply  with 
requirements (z).  
 
Because cosmetics in general are considered to cause less risks to health, the rules are less 
stringent than for drugs, which are seen as inherently risky. This is already clear from the 
longer list of factors that could cause a drug to be classified as misbranded or adulterated. For 
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example,  drugs  need  in  general  the  IND/NDA  procedure  for  approval.  Preclinical 
toxicological testing, clinical testing under an investigational new drug application (IND), 
submission  of  a  new  drug  application  (NDA)  to  get  FDA  approval  and  post-approval 
requirements, like good manufacturing practices, are all mandatory.
165 A drug is regulated 
differently depending on its type in the U.S.: prescription or nonprescription (also known as 
over-the-counter - OTC). It is therefore important to discuss both classes. Prescription drugs 
cannot  be  OTC  drugs  because  they  are  either  toxic  or  harmful,  or  only  safe  under  the 
supervision of a doctor.
166 In general, a new drug will need a New Drug Application (NDA) 
in order to enter into interstate commerce. There is an exception in case the drug is Generally 
Recognized as Safe and Effective (GRAS/E). In the Drug Amendments of 1962, Congress 
mandated that all drugs, including OTC drugs, be reviewed for effectiveness.
167 FDA then 
created the OTC monograph system. Drugs were reviewed and could be classified as GRAS/E 
upon review by expert panels.
168 From 1972 to 1983, reports were indeed established by 
advisory review panels of experts that evaluated the safety and effectiveness of  OTC drugs' 
active ingredients and reviewed the labels. When the “OTC Drug Review” was finished, a 
report was sent to the Commissioner of FDA, who would publish as last step in the procedure, 
the final monographs. All reports were published in 1983 although not all monographs are 
final  yet.
169  These  monographs,  which  are  published  in  the  Federal  Register,  contain 
requirements for categories of nonprescription drugs, such as what ingredients may be used 
and for what intended use. The benefit of this system is that drugs falling within an OTC 
monograph (thus considered GRAS/E) did not need to get NDA approval. In turn, when 
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ingredients do not fall within a monograph that states that it is GRAS/GRAE, they need to get 
NDA before entering the market.  
The monograph system for OTC drugs makes it possible to approve products in a short 
period of time. Cosmetic drugs such as our cream could be seen as OTC drugs, now that the 
OTC Drug Review has been reformed in 1997.
170 If the effects and active ingredients and 
labels  fall  within  an  OTC  monograph,  the  cosmetic  would  be  an  OTC  drug  and  not  a 
prescription  drug.
171  No  pre-approval  is  necessary  then.  The  manufacturer  only  needs  to 
request monograph status for the product. Stem cells nevertheless might not fall within an 
existing OTC monograph. This would mean that the stem cells in the cream would make it a 
prescription drug if there are also structure/function claims. The premarket NDA approval 
procedure is then the only possibility. Although my main conclusion seems to be that the U.S. 
under-regulates our cream, the situation is different here. I do see this as overregulation for 
the cream that only claims to influence the stem cells in the skin but that has no proof that it 
actually does. In Europe, this would still be classified as a cosmetic. Here it would probably 
be considered a prescription drug (see infra on Jaba Labs). On the other hand, I have to admit 
that the manufacturer would easily avoid this problem by removing the claim. I,  however, do 
not see this as overregulation for the cream containing human stem cell extracts. In Europe, a 
similar cream would follow the same approval procedure. 
 
It is not true that an OTC drug, now it does not need to get the NDA approval, is not 
sufficiently  regulated.  Production  facilities  must  be  listed  with  FDA.
172  Besides  reporting 
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product  related  injuries  to  FDA,  production  facilities  must  meet  stringent  drug  GMP 
procedures.
173 FDA facility inspections are even a part of the regulation. 
174  
FDA can also send regulatory letters to the company.
175 An example is the Warning 
Letter Jaba Labs received about its products StemCellin Intensive Emulsion and StemCellin 
Deep Wrinkle Serum StemCellin®. These are both facial creams that claimed on their website 
to “activate your own skin stem cells”, “delays deterioration of essential skin cells”, “reverses 
chronological aging”, etc. FDA stated that the claims establish that these products are drugs 
because they are structure/function claims.
176 As a drug, the product was not seen as GRAS/E. 
Only  with  NDA  approval  could  they  market  the  way  they  did.  They  were  therefore 
adulterated.  
The prescription drug approval procedure often takes a decade or more and is also 
very costly.
177 Many cosmetic manufacturers will therefore decide not to invest in it. Did this 
mean that the stem cell cream had to leave the market unless it started an NDA? No. FDA 
already referred to another solution. It declared that the labeling and other claims were not in 
compliance  with  the  applicable  laws  and  regulation.  It  was  therefore  an  example  of  a 
misbranded drug. The drug claims made the creams drugs that failed to comply with the drug 
labeling requirements.
178 The violations should be promptly corrected. Otherwise seizure or 
injunctions  could  follow.  In  reality,  the  manufacturer  changed  the  website.
179  For  FDA's 
purposes,  this  is  sufficient.  This  means  that  a  potentially  unsafe  product  can  stay  on  the 
market in the U.S. as long as the manufacturer changes it's claims.  
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Two of FDA’s rationales to classify a product asa drug are to ensure safety and to 
prevent the use of ineffective ingredients in products that come off as drugs.
180 Classifying 
them  as  drugs  is  an  important  measure  given  that  FDA  does  not  control  the  safety  of 
cosmetics in the same way. Although most cosmetic drugs avoid pre-approval requirements 
by conforming to the requirements in an (OTC) drug monograph, in the case of Jaba Labs this 
was not possible.
181 FDA's dual goals are clearly not met through the current practice where 
companies have the option of simply modifying the claims they make with respect to the 
drugs.  An  example  of  a  product  that  does  not  want  to  fall  within  the  scope  of  the  drug 
regulation  is  Dior’s  R60/80  Xp.  It  claims  on  its  website  that  “wrinkles  seem
182 
IMMEDIATELY  smoothed,  INTENSELY  reduced  after  1  month,  LASTINGLY  restored 
after 3 months”.
183 Amatokin, however, used to make claims such as "rejuvenates the skin and 
makes  you  look  younger  …  a  lot  younger"  in  the  past  and  found  itself  facing  legal 
repercussions as these claims were not scientifically proven. Today, these claims have been 
removed from their website.
184 The problem is thus solved for the FDA and Amatokin, but not 
for the consumers in terms of their safety. If the product is seen to be as hazardous as it was 
previously at the time the claims were made, the consumers' health remains in jeopardy.   
 
    (3) Conclusion 
A cosmetic that claims to work into the skin’s stem cells would be qualified as a drug 
in the U.S. Adjusting the claim is an easy way to comply with the rules (as the cosmetic 
would then no longer be misbranded or adulterated) while concurrently avoiding the strict(er) 
                                                 
180 Margaret Gilhooley, Cosmetic Regulation: Going Beyond Appearance, SEVENTY-FIFTH ANNIVERSARY 
COMMEMORATIVE  VOLUME OF  FOOD AND DRUG LAW  323, 323-24 (Food & Drug Law Inst. ed., 1984). 
181 Greff, supra note 50, at 243 and 253. 
182 Emphasis added. 
183 http://www.dior.com/beauty/usa/en/skin_care_by_christian_dior_face_care_body_care_su/face-
skincare/wrinkle_correction/ridesdaynight/ultimate-wrinkle-restoring-serum/py0535530.html 
184 http://www.cosmeticsdesign.com/Product-Categories/Cosmeceuticals/Stem-cell-cream-gets-into-marketing-
trouble   41 
drug regulations. Case closed for FDA but the product is still the same and therefore, could be 
injurious.  
In Europe this is not possible. The claim would only make the cream a drug if the 
effects are proven to be scientifically true. Even if it stays classified as a cosmetic, the safety 
of the product is assured as Europe does have safety assessment requirements for cosmetics. 
The  U.S.  lacks  such  mandatory  cosmetic  safety  regulations  and  therefore,  underregulates 
creams containing stem cell extracts that are prohibited from being classified as cosmetics in 
Europe. 
 
 
III. Conclusion and Recommendations 
 
  Cosmetics have changed over time. New innovations have altered the possible 
ingredients and effects of these products. Some companies produce creams with so-called 
properties  of  working  on  the  consumer’s  body’s  stem  cells.  If  these  claims  are  true,  the 
product could potentially be hazardous. An even more urgent matter concerns the ingredients 
of cosmetics. In the U.S., almost all ingredients are allowed to be used in cosmetics. Human 
cell  (extracts)  can  contain  many  diseases  if  not  handled  carefully.  By  allowing  creams 
containing human stem cells to be marketed with no mandatory safety assessment, the U.S. 
continues to put its citizens in jeopardy.  
In my opinion, the goal is to put only safe cosmetics on the market. I think this can 
only be achieved if there is a mandatory safety assessment with (arguably) a list of prohibited 
or restricted ingredients. This is already the situation in Europe.  
A drawback of this rule could be that manufacturers become unwilling to offer the 
product or alternatively, that the products' prices skyrocket. This could lead to less innovative   42 
cosmetics. Nevertheless, a choice has to be made and in my view, safety ought to be treated as 
priority number one. Based on my analysis of stem cell creams, I view that FDA’s regulation 
of cosmetics is insufficient to protect consumers against today’s new innovations. In the U.S., 
an example of a solution to this problem would be to extend premarket safety requirements to 
apply to cosmetics, as is currently done in Europe. Premarket authorization, as is currently 
required for drugs, would not be necessary.
185  
 
Moreover, it seems almost unbelievable that something as trivial as the wordings on a 
website can change the rules applicable in the U.S. from a very lenient set of regulations to 
very strict regulations … and back. This implies that creams that are potentially hazardous 
would  almost  always  fall  between  the  cracks  and  escape  safety  regulation  altogether.  In 
Europe, however, a product that could be injurious will need to follow the rigorous, expensive 
and time consuming drug regulations. Claims have no influence on the products discussed in 
this paper, but the cream’s properties do. 
I think the dual division between cosmetics and drugs in the U.S. is sufficient. A third 
category of so called cosmeceuticals or borderline products should not get different regulation 
(as for instance is the case in Japan
186). A dual division is acceptable but the criterion, i.e. 
solely on the basis of claims by manufacturers, on which this happens is not. Let superficiality 
be used to explain how a product has to be applied but let it not rule a decision as important as 
the applicable regulatory category: drug or cosmetic. 
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